Stéphane Benoist
Stéphane Benoist is an expert in Surgery at Bicêtre Hospital (France). As of October 2026, ScienceLeadR ranks Stéphane Benoist in the top 1% of experts worldwide for Rectal Diseases, Intestinal Neoplasms and Gastrointestinal Neoplasms. Stéphane Benoist has authored 301 publications, the most recent in 2026, and is an investigator in 24 clinical trials, 8 of them ongoing. SLR score: 1,058 (community average: 125). How the SLR is computed.
LeadR Profile
Surgery
Subspecialties: Oncology - Gastroenterology - Public Health
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1995 - 2026
Number : 301
Citations
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Preoperative High-Dose Corticosteroids in Digestive Cancer Surgery: A Randomized Clinical Trial. PMID 42616512 — methylprednisolone, intraabdominal infections, surgical procedures, operative, adrenal cortex hormones, neoplasms, wound infection, infections, postoperative complications | JAMA Surg | 2026 | 0 |
| Transanal Endoscopic Microsurgery or Endoscopic Submucosal Dissection in Early Rectal Tumors: A Clinical and Cost-Effectiveness Analysis: The MUCEM Study. PMID 41620037 — transanal endoscopic microsurgery, quality of life, confidence intervals, neoplasms, rectal neoplasms, microsurgery, dissection, endoscopic mucosal resection, survival rate | Gastroenterology | 2026 | 0 |
| Organ Preservation in Rectal Cancer Management: A Prospective GRECCAR Snapshot. PMID 42053078 — disease-free survival, organ preservation, neoplasms, neoplasm metastasis, neoadjuvant therapy, rectal neoplasms, therapeutics | Dis Colon Rectum | 2026 | 0 |
| Neoadjuvant chemotherapy for obstructive colon cancer derived by a stoma: Study protocol of the FRENCH-01 randomized phase III trial (COnCERTO Trial). PMID 41945039 — quality of life, neoplasms, colon, drug therapy, chemotherapy, adjuvant, morbidity, colectomy, colonic neoplasms, chemotherapy | Dig Liver Dis | 2026 | 0 |
| Long-term parietal complications following surgery for inflammatory colitis: An underestimated issue. PMID 41619434 — hernia, colitis, incidence, risk factors, prolapse, incisional hernia | Surgery | 2026 | 0 |
Clinical Studies 24
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Cohort/Consortium Investigators 6
Ongoing Clinical Trials
8 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| metastatic colorectal cancer 2023-504831-42-00 — neoplasms, drug therapy, liver, neoplasm metastasis, therapeutics, colorectal neoplasms, chemotherapy | Phase 3 | Recruiting | 2025 |
| FOLFIRINOX Induction Chemotherapy for Synchronous Liver Metastases NCT07467434 — antineoplastic combined chemotherapy protocols, induction chemotherapy, antineoplastic agents, neoplasms, cohort studies, drug therapy, liver, neoplasm metastasis, rectal neoplasms, therapeutics, chemotherapy | N/A | Recruiting | 2026 |
| Risk adapted adjuvant chemotherapy guided by the tumour stage for operated pancreatic adenocarcinoma following neoadjuvant chemotherapy with FOLFIRINOX FRENCH26 PRODIGE93 PANACHE02 Trial 2024-519048-33-00 — adenocarcinoma, drug therapy, chemotherapy, adjuvant, therapeutics, chemotherapy | Phase 2/Phase 3 | Recruiting | 2025 |
| Adjuvant FOLFIRI Based chemotherapy After Resection of CLM Responding to Preoperative FOLFIRI NCT06501482 — leucovorin, disease-free survival, neoplasms, drug therapy, liver, fluorouracil, neoplasm metastasis, therapeutics, colorectal neoplasms, irinotecan, chemotherapy | Phase 3 | Recruiting | 2025 |
| Interest of Early Erectile Rehabilitation With Sildenafil After Radiotherapy and Proctectomy for Rectal Cancer NCT06123156 — radiotherapy, neoplasms, rehabilitation, sildenafil citrate, rectum, proctectomy, rectal neoplasms, blood platelets | Phase 3 | Recruiting | 2025 |
LeadR Networks
Main global connection map